What is the price target for AAPG stock?
13 analysts have analysed AAPG and the average price target is 49.82 USD. This implies a price increase of 113.44% is expected in the next year compared to the current price of 23.34.
ASCENTAGE PHARMA GR-ADR (AAPG) Forecast, Price Target & Analyst Ratings
NASDAQ:AAPG
Current stock price
23.34 USD
+0.46 (+2.03%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASCENTAGE PHARMA GR-ADR (AAPG).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$49.82
Upside
+ 113.44%
From current price of $23.34 to mean target of $49.82, Based on 13 analyst forecasts
Low
$36.88
Median
$51.19
High
$61.39
Price Target Revisions
1 Month
55.06%
3 Months
40.03%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for AAPG. The average price target is 49.82 USD. This implies a price increase of 113.44% is expected in the next year compared to the current price of 23.34.
The average price target has been revised upward by 40.03% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.15%
AAPG was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about AAPG.
In the previous month the buy percentage consensus was at a similar level.
AAPG was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-13 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-26 | BTIG | Reiterate | Buy -> Buy |
| 2025-12-04 | Oppenheimer | Initiate | Outperform |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-10 | BTIG | Initiate | Buy |
| 2025-11-05 | Piper Sandler | Initiate | Overweight |
| 2025-03-27 | JP Morgan | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 221.984M 5.85% | 980.65M 341.77% | 574.12M -41.46% | 2.241B 290.34% | 1.878B -16.20% | 2.405B 28.06% | 3.003B 24.86% | 4.587B 52.75% | 6.252B 36.30% | 8.367B 33.83% | 10.32B 23.34% | |
| EBITDA YoY % growth | -796.726M -0.66% | -281.002M 64.73% | N/A -245.06% | 290.06M 129.91% | -195.921M -167.55% | 161.1M 182.23% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -874.038M -2.47% | -374.171M 57.19% | -1.182B -215.98% | 609.68M 151.57% | -254.591M -141.76% | -246.196M 3.30% | -181.81M 26.15% | 690.12M 479.58% | 2.862B 314.71% | 4.565B 59.50% | 6.106B 33.76% | |
| Operating Margin | -393.74% | -38.16% | -205.93% | 27.21% | -13.56% | -10.24% | -6.05% | 15.05% | 45.78% | 54.56% | 59.17% | |
| EPS YoY % growth | N/A 12.05% | N/A 61.78% | N/A -185.96% | 4.84 138.64% | -1.38 -128.53% | 0.53 138.32% | -22.19 -4,297.92% | -0.55 97.50% | N/A | N/A | N/A |
All data in CNY
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CNY
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
26.87%
EPS Next 5 Year
14.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
59.02%
Revenue Next 5 Year
50.30%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
29.14%
EBIT Next 5 Year
N/A
ASCENTAGE PHARMA GR-ADR / AAPG Forecast FAQ
What is the expected long term growth rate for AAPG stock?
The expected long term growth rate for ASCENTAGE PHARMA GR-ADR (AAPG) is 59.02%.